Utilizing kidneys from a donor with bile-cast nephropathy

The use of high-risk deceased donor kidneys remains controversial. Prior research has shown that kidneys with acute kidney injury are often discarded despite potential for successful transplantation. No prior work had resolved whether bile-cast nephropathy is reversible after transplantation. This gap motivated a closer examination of donor kidneys with cholemic injury. Established knowledge includes the association of elevated bilirubin with renal dysfunction. However, the long-term outcomes of transplanted kidneys with bile casts remain unclear. The potential for reversible cholemic injury has not been well documented in clinical practice. This paper's contribution lies in demonstrating functional recovery in such cases.

This case report aimed to evaluate the viability of kidneys from a donor with bile-cast nephropathy. The specific problem addressed is the underutilization of high-risk donor kidneys due to concerns about bile-cast nephropathy. The motivation stems from the need to expand the donor pool without compromising recipient outcomes. The study focused on whether cholemic injury is reversible post-transplantation. The goal was to assess both short-term and 4-month outcomes in two recipients. The researchers sought to determine if these kidneys could be safely transplanted. The study also aimed to provide evidence for reconsidering the discard criteria for such kidneys. This approach could influence future donor kidney utilization practices.

The study involved a retrospective analysis of two deceased donor kidney transplants. The donor had a kidney donor profile index of 48% and required renal replacement therapy. Peak bilirubin levels were recorded at 40.5 mg/dL. Renal wedge biopsies confirmed bile-cast nephropathy. Both recipients experienced delayed graft function lasting up to 4 weeks. Follow-up biopsies were performed at the 4-month mark. Histological changes were analyzed for interstitial fibrosis and tubular atrophy. The researchers evaluated whether bile casts resolved over time.

Both recipients experienced delayed graft function lasting up to 28 days post-transplantation. The 4-month biopsies showed mild interstitial fibrosis in both cases. Tubular atrophy was observed but remained mild. Bile casts were no longer present in the 4-month biopsies. This finding suggests a resolution of cholemic injury. The kidney donor profile index of 48% indicated moderate donor risk. The peak bilirubin level of 40.5 mg/dL highlighted significant cholemic injury. These results suggest that bile-cast nephropathy may be reversible post-transplantation.

The authors suggest that kidneys with bile-cast nephropathy may still be viable for transplantation. The resolution of bile casts at 4 months indicates a potentially reversible condition. The mild histological changes observed do not preclude long-term function. The study implies that current discard criteria may be too restrictive. The findings support a reevaluation of donor kidney selection protocols. These kidneys demonstrated functional recovery despite initial cholemic injury. The authors propose that such kidneys could expand the donor pool without compromising outcomes. This approach may increase the utilization of previously discarded kidneys.